Table 2.
Key Oncogene Mutation Spectrum
| Oncogene Mutation | No. a | % b | Oncogene Mutation | No. a | % b |
|---|---|---|---|---|---|
| EGFR driver mutations, n = 1418 mutations in 1361 patients c | ERBB2 mutations, n = 126 mutations in 124 patients | ||||
| Exon 19 deletions | 705 | 51.8 | Exon 20 insertion | 76 | 61.3 |
| L858R | 468 | 34.4 | S310F, S310Y | 16 | 12.9 |
| G719A, G719C, G719D, G719R, G719S | 66 | 4.8 | V659E | 7 | 5.6 |
| Exon 20 insertion | 61 | 4.5 | L755P, L755S, L755A | 6 | 4.8 |
| L861Q, L861R | 38 | 2.8 | V777L | 4 | 3.2 |
| S768I | 19 | 1.4 | V842I | 3 | 2.4 |
| L833V | 9 | 0.7 | D769Y, D769D | 3 | 2.4 |
| Others | 52 | 3.8 | Others | 11 | 8.9 |
| KRAS mutations, n = 910 mutations in 888 patients c | ALK fusions, n = 65 | ||||
| G12C, G12V, G12D, G12A, G12S, G12F, G12R, G12E | 716 | 80.6 | EML4‐ALK fusion | 58 | 89.2 |
| G13C, G13D, G13E, G13F, G13P, G13R, G13V | 72 | 8.1 | STRN‐ALK fusion | 3 | 4.6 |
| Q61H, Q61L, Q61R, Q61K | 72 | 8.1 | KLC1‐ALK fusion | 2 | 3.1 |
| V14I | 10 | 1.1 | KIF5B‐ALK fusion | 1 | 1.5 |
| A146V, A146T, A146P | 10 | 1.1 | TFG‐ALK fusion | 1 | 1.5 |
| Others | 30 | 3.4 | |||
| BRAF mutations, n = 142 mutations in 139 patients | ROS1 fusions, n = 9 mutations | ||||
| V600E, V600K | 56 | 40.3 | CD74‐ROS1 fusion | 5 | 55.6 |
| G469A, G469V, G469R, G469E | 31 | 22.3 | EZR‐ROS1 fusion | 2 | 22.2 |
| G466V, G466R, G466A | 12 | 8.6 | SDC4‐ROS1 fusion | 1 | 11.1 |
| N581S | 11 | 7.9 | TPM3‐ROS1 fusion | 1 | 11.1 |
| K601E | 7 | 5.0 | RET fusions, n = 45 | ||
| D594G, D594A | 5 | 3.6 | KIF5B‐RET fusion | 28 | 62.2 |
| G596R, G596 | 4 | 2.9 | CCDC6‐RET fusion | 13 | 28.9 |
| Others | 16 | 11.5 | NCOA4‐RET fusion | 4 | 8.9 |
a
No. indicates the number of mutations identified.
b
The percentage (%) indicates the proportion of patients with a mutation in that gene who had the respective mutation.
c
Double mutation profiles are detailed in Supporting Tables 6 and 8.